Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HROW, SLRN, OCUL, TGTX, RYTM, and represent 48.44% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: TGTX (+$16M), CPRX (+$14M), Gossamer Bio, APLT, OCUL, IGMS, PGEN, GOSS, FDMT, VSTM.
- Started 8 new stock positions in TGTX, BDSX, XERS, PGEN, Gossamer Bio, RLMD, APLT, CPRX.
- Reduced shares in these 10 stocks: CRNX (-$14M), TELA (-$6.6M), CBAY (-$6.2M), TBPH (-$5.6M), THRX (-$5.6M), ACAD (-$5.2M), NTLA, PCVX, CYTK, EDAP.
- Sold out of its positions in ACAD, ATXS, BDTX, CBAY, CYTK, EDAP, FULC, NTLA, Jounce Therapeutics, KPTI. STXS, STRO, THRX, TBPH, PRQR.
- Opaleye Management was a net seller of stock by $-43M.
- Opaleye Management has $305M in assets under management (AUM), dropping by -27.02%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opaleye Management
Opaleye Management holds 40 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Harrow Health (HROW) | 17.9 | $55M | 3.8M | 14.37 |
|
|
| Acelyrin (SLRN) | 13.8 | $42M | 4.1M | 10.17 |
|
|
| Ocular Therapeutix (OCUL) | 6.7 | $20M | +11% | 6.5M | 3.14 |
|
| Tg Therapeutics (TGTX) | 5.2 | $16M | NEW | 1.9M | 8.36 |
|
| Rhythm Pharmaceuticals (RYTM) | 4.9 | $15M | -11% | 653k | 22.93 |
|
| Catalyst Pharmaceutical Partners (CPRX) | 4.6 | $14M | NEW | 1.2M | 11.69 |
|
| Keros Therapeutics (KROS) | 3.8 | $12M | +2% | 360k | 31.88 |
|
| Biohaven (BHVN) | 3.7 | $11M | -18% | 439k | 26.01 |
|
| Crinetics Pharmaceuticals In (CRNX) | 3.6 | $11M | -56% | 370k | 29.74 |
|
| Eton Pharmaceuticals (ETON) | 3.3 | $10M | +6% | 2.4M | 4.17 |
|
| Ideaya Biosciences (IDYA) | 2.8 | $8.4M | -24% | 312k | 26.98 |
|
| Morphosys Sponsored Ads (MOR) | 2.7 | $8.1M | 1.2M | 6.72 |
|
|
| Tela Bio (TELA) | 2.0 | $6.0M | -52% | 750k | 8.00 |
|
| Edgewise Therapeutics (EWTX) | 1.6 | $5.0M | +7% | 875k | 5.73 |
|
| Kalvista Pharmaceuticals (KALV) | 1.6 | $4.8M | -30% | 500k | 9.63 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 1.5 | $4.7M | -6% | 584k | 8.05 |
|
| Vaxcyte (PCVX) | 1.5 | $4.6M | -49% | 90k | 50.98 |
|
| Protara Therapeutics Com Stk (TARA) | 1.5 | $4.5M | 2.7M | 1.67 |
|
|
| Urogen Pharma (URGN) | 1.5 | $4.5M | -43% | 320k | 14.01 |
|
| Geron Corporation (GERN) | 1.3 | $4.1M | -18% | 1.9M | 2.12 |
|
| Gossamer Bio (GOSS) | 1.3 | $4.0M | +41% | 4.8M | 0.83 |
|
| 4d Molecular Therapeutics In (FDMT) | 1.3 | $3.9M | +39% | 309k | 12.73 |
|
| Xoma Corp Del Com New (XOMA) | 1.3 | $3.9M | 275k | 14.09 |
|
|
| Trevi Therapeutics (TRVI) | 1.2 | $3.7M | 1.7M | 2.18 |
|
|
| Liquidia Corporation Com New (LQDA) | 1.2 | $3.6M | 571k | 6.34 |
|
|
| Larimar Therapeutics (LRMR) | 1.1 | $3.4M | -38% | 849k | 3.95 |
|
| Nyxoah S A SHS (NYXH) | 1.0 | $3.1M | 442k | 7.05 |
|
|
| Gossamer Bio Note 5.000% 6/0 | 1.0 | $3.1M | NEW | 8.0M | 0.39 |
|
| Iovance Biotherapeutics (IOVA) | 0.9 | $2.8M | +44% | 610k | 4.55 |
|
| Applied Therapeutics (APLT) | 0.7 | $2.2M | NEW | 893k | 2.49 |
|
| Igm Biosciences (IGMS) | 0.7 | $2.2M | +311% | 261k | 8.35 |
|
| Codexis (CDXS) | 0.7 | $2.1M | +65% | 1.1M | 1.89 |
|
| Verastem Com New (VSTM) | 0.6 | $1.7M | +107% | 211k | 8.13 |
|
| Precigen (PGEN) | 0.4 | $1.3M | NEW | 929k | 1.42 |
|
| Tracon Pharmaceuticals Com New (TCON) | 0.3 | $848k | 4.8M | 0.18 |
|
|
| Biodesix (BDSX) | 0.2 | $752k | NEW | 456k | 1.65 |
|
| Xeris Pharmaceuticals (XERS) | 0.2 | $725k | NEW | 390k | 1.86 |
|
| Fortress Biotech (FBIO) | 0.2 | $581k | -39% | 2.0M | 0.29 |
|
| Kezar Life Sciences (KZR) | 0.2 | $506k | +330% | 425k | 1.19 |
|
| Relmada Therapeutics (RLMD) | 0.0 | $90k | NEW | 30k | 3.00 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023
- Opaleye Management 2022 Q4 filed Feb. 10, 2023
- Opaleye Management 2022 Q3 filed Nov. 14, 2022
- Opaleye Management 2022 Q2 filed Aug. 15, 2022
- Opaleye Management 2022 Q1 filed May 16, 2022
- Opaleye Management 2021 Q4 filed Feb. 14, 2022
- Opaleye Management 2021 Q3 filed Nov. 16, 2021
- Opaleye Management 2021 Q2 filed Aug. 16, 2021
- Opaleye Management 2021 Q1 filed May 18, 2021
- Opaleye Management 2020 Q4 filed Feb. 12, 2021
- Opaleye Management 2020 Q3 filed Nov. 16, 2020
- Opaleye Management 2020 Q2 filed Aug. 14, 2020
- Opaleye Management 2020 Q1 filed May 15, 2020
- Opaleye Management 2019 Q4 filed Feb. 14, 2020